Liquidia FY25 earnings call LQDA

Liquidia's YUTREPIA demonstrated rapid market establishment, achieving $148.3 million in net product sales for FY25 and $90.1 million in Q4 2025, marking a 74% sequential growth. The company reported over 3,600 unique patient referrals and 2,900 patients shipped therapy since launch as of February 28, 2026. This momentum has led to a significant increase in market share, accounting for over 100% of the inhaled treprostinil market growth in Q4 2025, with its revenue share rising from 10% in Q3 to 17% in Q4.

Liquidia is pursuing a disciplined expansion of its clinical evidence for YUTREPIA and L606. This includes initiating new studies to transition patients from existing oral and inhaled prostacyclin therapies, as well as exploring adjunctive use with sotatercept. The company also plans to expand YUTREPIA into new disease areas such as systemic sclerosis-associated Raynaud's phenomenon and PH-COPD, with a Phase IIa program for systemic sclerosis RP expected to start by year-end 2026. The next-generation L606 pivotal study has been initiated in multiple territories, with enrollment anticipated in the coming quarters^⏳.

The company achieved significant financial milestones in Q4 2025, reporting non-GAAP adjusted EBITDA of $27.3 million and net income of $14.6 million. Liquidia generated $33 million in positive cash flow during the quarter, ending the year with approximately $190.7 million in cash and cash equivalents. Management emphasized that these operational cash flows will fund future clinical development, supporting the goal of building a durable franchise with increasing patient preference and a clear path to at least $1 billion in sales by 2027.

Management addressed emerging competitive dynamics, including a new oral prostacyclin (ralinepag) and a soft mist inhaler (SMI) from a competitor. They asserted that ralinepag's profile is similar to UPTRAVI, with muted symptomatic benefits and significant GI side effects, thus not impacting YUTREPIA's launch. Similarly, the SMI was described as a repurposed technology for Tyvaso solution, not offering improved tolerability or lower airway penetration, and therefore not viewed as competitive. Liquidia highlighted YUTREPIA's deep-lung delivery, low-effort device, and wide dose range as key differentiators.

Liquidia reported maintaining an impressive 85%+ prescription to patient start conversion rate, indicating strong payer access. While a small incremental increase in gross-to-net is expected in 2026 due to more rebates, this is offset by broader patient access. On the legal front, the company is awaiting an opinion on the 793 patent oral hearing, which occurred in June 2025, with post-trial briefings completed in August 2025. Management expressed confidence in their position and readiness for any outcome, despite the delay in the ruling.